Short Interest in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Decreases By 14.6%

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totaling 5,491,622 shares, a decrease of 14.6% from the March 15th total of 6,433,712 shares. Approximately 10.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 10,152,747 shares, the days-to-cover ratio is presently 0.5 days.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Negative Sentiment: Rosen Law Firm reminded Aldeyra investors of the May 29, 2026 lead‑plaintiff deadline in the securities class action it first filed; invites affected purchasers to secure counsel. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ALDX
• Negative Sentiment: Kirby McInerney LLP issued a shareholder alert urging Aldeyra purchasers to contact the firm by May 29, 2026 to discuss claims in the securities fraud class action. ALDX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Aldeyra Therapeutics Investors – Contact Kirby McInerney LLP by May 29, 2026
• Negative Sentiment: The Schall Law Firm says investors may pursue leadership in a suit alleging violations of Sections 10(b) and 20(a) and Rule 10b‑5 for purchases during the stated class period. ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The Gross Law Firm issued a shareholder alert inviting investors with losses to join the class action covering the same class period. ALDX Shareholder Alert: Aldeyra Therapeutics, Inc Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
• Negative Sentiment: Faruqi & Faruqi, LLP reminds investors of the May 29 deadline and is investigating potential claims against Aldeyra for purchases within the class period. ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
• Negative Sentiment: Pomerantz LLP issued an investor alert about the class action and upcoming deadlines for shareholders with losses. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
• Negative Sentiment: SueWallSt’s alert alleges executives “allegedly disregarded FDA requirements” and reiterates the May 29 deadline for lead‑plaintiff motions — language that may heighten investor concern about regulatory and disclosure risks. ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: SueWallSt
• Negative Sentiment: Robbins LLP notified ADLX stockholders about the class action and invited those who lost money to contact the firm about leading the suit. Robbins LLP Encourages ADLX Stockholders Who Lost Money Investing in Aldeyra Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

Insider Buying and Selling

In related news, Director Richard Douglas acquired 70,000 shares of the stock in a transaction on Thursday, March 19th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the purchase, the director directly owned 195,000 shares in the company, valued at approximately $273,000. The trade was a 56.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Krilogy Financial LLC acquired a new stake in shares of Aldeyra Therapeutics in the 1st quarter valued at approximately $26,000. Caption Management LLC increased its position in Aldeyra Therapeutics by 110.6% during the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares in the last quarter. Inspirion Wealth Advisors LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at approximately $52,000. Global Retirement Partners LLC acquired a new stake in Aldeyra Therapeutics in the fourth quarter valued at approximately $52,000. Finally, BNP Paribas Financial Markets boosted its position in Aldeyra Therapeutics by 36.9% in the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 2,859 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Price Performance

NASDAQ ALDX opened at $1.80 on Friday. The business has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $4.51. The stock has a market capitalization of $108.32 million, a PE ratio of -3.16 and a beta of 1.34. Aldeyra Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $6.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts expect that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.